Related Experiment Video
Updated: May 1, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
Increased mean platelet volume is associated with non-responsiveness to clopidogrel
1Shlomi Matetzky, MD, Heart Institute, Sheba Medical Center, Tel Hashomer 52621, Israel, Tel.: +972 3 6352303, Fax: +972 3 534 3888,
Thrombosis and Haemostasis
|April 4, 2014
Summary
Increased mean platelet volume (MPV) predicts poor response to clopidogrel in acute coronary syndrome patients. This finding is crucial for optimizing antiplatelet therapy and improving clinical outcomes in this vulnerable population.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Individual variability in clopidogrel response impacts clinical outcomes.
- Factors influencing clopidogrel response in stable CAD are known, but not in acute coronary syndrome (ACS).
Purpose of the Study:
- To identify determinants of platelet response to clopidogrel in patients with acute myocardial infarction (AMI).
Main Methods:
- Adenosine diphosphate (ADP)-induced platelet aggregation (PA), hs-CRP, platelet count, and MPV were measured 72 hours post-clopidogrel loading in 276 AMI patients.
- Patients with ADP-induced PA ≥ 70% were classified as non-responders.
Main Results:
- 30% of patients were clopidogrel non-responders (n=84) versus 70% responders (n=192).
- Non-responders had significantly higher mean MPV (9 ± 1.2 fl vs 8 ± 1 fl, p=0.0018).
- ADP-induced PA increased significantly across MPV quartiles (p<0.001).
Conclusions:
- Increased MPV is associated with platelet activation and predicts non-responsiveness to clopidogrel in ACS patients.
- MPV may serve as a biomarker to guide antiplatelet therapy selection in AMI.
- Further research is warranted to validate MPV as a predictive marker for clopidogrel response.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
01:22Formation of the Platelet Plug
6.2K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.2K
01:18Structure and Function of Platelets
7.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
7.1K
01:24Disorders of Hemostasis
2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:05Introduction to Hemostasis
14.2K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.2K